NCT00301184View on ClinicalTrials.gov

Safety of and Immune Response to a DNA HIV Vaccine (pGA2/JS7) Boosted With a Modified Vaccinia HIV Vaccine (MVA/HIV62) in Healthy Adults

PHASE1CompletedINTERVENTIONAL
Enrollment

120

Participants

Timeline

Start Date

April 30, 2006

Study Completion Date

December 31, 2008

Conditions
HIV Infections
Interventions
BIOLOGICAL

pGA2/JS7 DNA

DNA Vaccine

BIOLOGICAL

Modified vaccinia Ankara/HIV62

Recombinant Modified Ankara Vaccine

Trial Locations (6)

21201

Project Brave HIV Vaccine CRS, Baltimore

37232

Vanderbilt Vaccine CRS, Nashville

35294-2041

Alabama Vaccine CRS, Birmingham

02115

Brigham and Women's Hosp. CRS, Boston

63110-2500

Saint Louis Univ. School of Medicine, HVTU, St Louis

14642-0001

Univ. of Rochester HVTN CRS, Rochester

All Listed Sponsors
collaborator

HIV Vaccine Trials Network

NETWORK

lead

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

NCT00301184 - Safety of and Immune Response to a DNA HIV Vaccine (pGA2/JS7) Boosted With a Modified Vaccinia HIV Vaccine (MVA/HIV62) in Healthy Adults | Biotech Hunter | Biotech Hunter